Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplant through Engineered Stem Cell Antibody Paired Evasion (ESCAPE)

Blood (2023) 142 (Supplement 1): 7128.

https://doi.org/10.1182/blood-2023-182077

Published: 2023

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Blood (2023) 142 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2023-185034

Published: 2023

Journal Articles

TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice

Ji Eun Lim, Srideshikan Sargur Madabushi, Hemendra Ghimire, Richardson Kimberly K, Paresh Vishwasrao, Amr M H Abdelhamid, Jeffrey Wong, Cynthia Aristei, Ha-Neui Kim, Daohong Zhou, Monzr M. Al Malki, Susanta Hui

Blood (2023) 142 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2023-187062

Published: 2023

Journal Articles

The Bone Marrow-Targeted Conditioning Stress Test Demonstrates Vertebrae Niche Being More Radio-Tolerant Than Femur, Indicating Skeleton Resilience and Global Heterogeneity

Srideshikan Sargur Madabushi, Ji Eun Lim, Hemendra Ghimire, Jeffrey Wong, Anthony Stein, Amandeep Salhotra, Monzr M. Al Malki, Susanta Hui

Blood (2023) 142 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2023-190708

Published: 2023

Journal Articles

Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease

Blood (2022) 140 (Supplement 1): 10213–10214.

https://doi.org/10.1182/blood-2022-169257

Published: 2022

Journal Articles

Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies

Blood (2022) 140 (Supplement 1): 4487–4488.

https://doi.org/10.1182/blood-2022-169120

Published: 2022

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, PhD, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, MS, David Yamauchi, MD, Erasmus Kofi Poku, PharmD, Van Eric Biglang-awa, PharmD, John E. Shively, PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141114

Published: 2020

Journal Articles

Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience

Savita Dandapani, MD PhD, Geoffrey Shouse, DO, PhD, Jekwon Yeh, MD, Thai Cao, MD, Jeffrey Wong, MD, Lihua E Budde, MD PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-143442

Published: 2020

Journal Articles

Targeted Marrow Radiation (TMI) Improves Therapeutic Efficacy of STAT3 Decoy Molecules By Augmenting Its Delivery and Immune Modulation in an AML Mouse Model

Srideshikan Sargur Madabushi, PhD, Darren Zuro, Yu-Lin SU, PhD, Paresh Vishwasrao, MSc, Jamison Brooks, B.S, Liliana E Parra, James F Sanchez, PhD, Jeffrey Wong, MD, Marcin Kortylewski, PhD, Susanta Hui, PhD, DABR.

Blood (2019) 134 (Supplement_1): 3929.

https://doi.org/10.1182/blood-2019-127470

Published: 2019

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, David Yamauchi, MD, Kofi Poku, PharmD, Van Biglang-awa, PharmD, John E. Shively

Blood (2018) 132 (Supplement 1): 611.

https://doi.org/10.1182/blood-2018-99-116907

Published: 2018

Journal Articles

64 cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

Srideshikan Sargur Madabushi, PhD, Darren Zuro, Jamison Brooks, B.S, Bijender Kumar, PhD, Liliana E Parra, Marvin Orellana, B.S, Indu Nair, PhD, Junie Chea, Kofi Poku, PharmD, Ching-Cheng Chen, PhD, James Sanchez, PhD, John E. Shively, Daniel A. Vallera, PhD, Jeffrey Wong, MD, Anthony S. Stein, MD, David Colcher, PhD, Paul Yazaki, PhD, Susanta Hui, PhD, DABR.

Blood (2018) 132 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2018-99-117878

Published: 2018

Journal Articles

A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 4607.

https://doi.org/10.1182/blood.V130.Suppl_1.4607.4607

Published: 2017

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Anthony Selwyn Stein, MD, Jeffrey Wong, MD, Joycelynne Palmer, PhD, Margaret O'Donnell, MD, David S. Snyder, MD, Ni-Chun Tsai, MS MPH, Pablo Parker, MD, Len Farol, MD, Ricardo Spielberger, MD, Firoozeh Sahebi, MD, Neil Kogut, MD, Joyce Murata-Collins, PhD, David Senitzer, PhD, Stephen J. Forman, MD

Blood (2012) 120 (21): 218.

https://doi.org/10.1182/blood.V120.21.218.218

Published: 2012

Journal Articles

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Joseph Rosenthal, Jeffrey Wong, Anthony Stein, Dajun Qian, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Sandra H. Thomas, Stephen Forman

Blood (2011) 117 (1): 309–315.

https://doi.org/10.1182/blood-2010-06-288357

Published: 2011

Journal Articles

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, MD, Jeffrey Wong, MD, Anthony Stein, MD, Ellen Bolotin, MD, PhD, Chatchada Karanes, MD, Leslie Popplwell, MD, Auayporn Nademanee, MD, Firoozeh Sahebi, MD, Margaret O’Donnell, MD, Maria Delioukina, MD, George Somlo, MD, Anna Pawlowska, MD, Debbie Hitt, RN, Marianna Shakhnovits, MD, Stephen Forman, MD

Blood (2007) 110 (11): 3021.

https://doi.org/10.1182/blood.V110.11.3021.3021

Published: 2007

Journal Articles

Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.

George Somlo, MD, Stephen Forman, MD, Leslie Poppelwell, MD, Tim Schultheiss, PhD, Paul Frankel, Ph.D, Amrita Krishnan, MD, An Liu, PhD, Firoozeh Sahebi, MD, Parker Pablo, MD, Jeffrey Wong, MD

Blood (2005) 106 (11): 1176.

https://doi.org/10.1182/blood.V106.11.1176.1176

Published: 2005

NARROW

Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplant through Engineered Stem Cell Antibody Paired Evasion (ESCAPE)

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice

The Bone Marrow-Targeted Conditioning Stress Test Demonstrates Vertebrae Niche Being More Radio-Tolerant Than Femur, Indicating Skeleton Resilience and Global Heterogeneity

Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease

Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience

Targeted Marrow Radiation (TMI) Improves Therapeutic Efficacy of STAT3 Decoy Molecules By Augmenting Its Delivery and Immune Modulation in an AML Mouse Model

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

64 cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only